A Study of the Rate of Progression of Glaucoma During a Follow-up Period of Two Years

This study has been completed.
Information provided by (Responsible Party):
ClinicalTrials.gov Identifier:
First received: June 25, 2012
Last updated: June 19, 2013
Last verified: June 2013
This is an epidemiological, non-interventional, prospective study to collect data on glaucoma progression in a routine setting. Patients may receive treatment at the discretion of their physician per local standard of care.

Condition Intervention
Glaucoma, Open-Angle
Other: Standard of Care

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective

Resource links provided by NLM:

Further study details as provided by Allergan:

Primary Outcome Measures:
  • Change from Baseline in Visual Field [ Time Frame: Baseline, 24 Months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change from Baseline in Intraocular Pressure (IOP) [ Time Frame: Baseline, 24 Months ] [ Designated as safety issue: No ]

Enrollment: 315
Study Start Date: June 2009
Study Completion Date: May 2013
Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Patients with glaucoma
Other: Standard of Care
Patients with glaucoma treated with standard of care at the discretion of the physician. There is no specific treatment required for this study.


Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with primary open angle glaucoma in one or both eyes

Inclusion Criteria:

  • Glaucoma in one or both eyes

Exclusion Criteria:

  • Participation in a glaucoma therapeutic clinical trial
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01629407

Barcelona, Spain
Sponsors and Collaborators
Study Director: Medical Director Allergan
  More Information

Responsible Party: Allergan
ClinicalTrials.gov Identifier: NCT01629407     History of Changes
Other Study ID Numbers: MAF/AGN/OPH/GLA/015 
Study First Received: June 25, 2012
Last Updated: June 19, 2013
Health Authority: Spain: Ethics Committee

Additional relevant MeSH terms:
Glaucoma, Open-Angle
Eye Diseases
Ocular Hypertension

ClinicalTrials.gov processed this record on May 26, 2016